Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences' stock price has experienced significant fluctuations over the past six months. The stock price increased by 141.93% over the last six months. As of January 9, 2026, the share price was $21.01, representing a 47.96% increase from January 10, 2025. The 52-week high for RCUS was $26.40, and the 52-week low was $6.50. Arcus Biosciences reported its Q3 2025 earnings, posting an EPS of -$1.27 and revenue of $26.00 million. Arcus Biosciences and Gilead discontinued the Phase 3 STAR-221 study in cancer due to futility. Analyst ratings have varied, with some firms setting a $30.00 price objective and others reiterating an "equal weight" rating. There was a reported instance of the Arcus Biosciences President selling $2 million in stock. The stock gapped up prior to trading on January 13, 2026, opening at $22.19 after closing at $21.30.

Arcus Biosciences' revenue is primarily derived from strategic collaborations and licensing agreements, so traditional demand seasonality does not directly apply. The company's financial performance and stock valuation are more influenced by clinical trial milestones, regulatory approvals, partnership developments, and overall biotechnology market sentiment. Historically, implied volatility for RCUS tended to rise the most in May and decline to its lowest levels in August, which could be a factor for options traders.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies. The company aims to transform cancer treatment by enhancing the immune system's ability to fight cancer, targeting key biological pathways. Its product pipeline includes investigational products like Domvanalimab, Etrumadenant, Quemliclustat, Casdatifan, and Zimberelimab, all in various phases of clinical development. The company's business model relies on strategic collaborations and licensing agreements, generating revenue from upfront payments, milestone achievements, and R&D reimbursement.

Arcus Biosciences is headquartered in Hayward, California, United States. While its primary operations are in the US, its collaborations with companies like Gilead Sciences and AstraZeneca suggest a broader reach in terms of clinical trials and potential market access.

Arcus Biosciences' brand reputation is tied to its clinical trial progress, strategic partnerships, and financial performance. The company is known for developing innovative cancer therapies and for its strong R&D efforts. Strategic partnerships enhance its credibility and potential market reach. Positive clinical trial results contribute to a favorable outlook. The discontinuation of the Phase 3 STAR-221 study could have negatively impacted its reputation. Financial challenges can also affect perception. Analyst sentiment is generally positive, reflecting confidence in its long-term potential.

Arcus Biosciences has a mixed ownership structure including institutional, retail, and individual investors. Institutional investors hold a significant portion of the stock, with approximately 83.01% to 94.7% institutional ownership. Gilead Sciences, Inc. is the largest institutional position, holding 29.53% of the company. Other major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Point72 Asset Management, L.P. Insiders own approximately 30.14% of the company's stock.